Home - Open Targets

Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.

Find targets for a given disease
Visit the Open Targets Platform Discover genetic evidence for targets
Visit Open Targets Genetics Explore our experimental projects
Read our research publications

News

A man in a blue shirt is standing on the balcony of an office building made of metal and glass. He is posing and smiling at the camera, left hand in his pocket and right hand resting on the balcony railing. Surrounding trees can be seen in the background and reflected in the building.

David Hulcoop appointed Open Targets Director

5 July 2023

July 5, Cambridge — Open Targets has appointed David Hulcoop as its new Executive Director, following the retirement of Ian Dunham. Hulcoop will build from the programme’s existing capabilities to maximise Open Targets impact on drug discovery decision making.

Open Targets, a public-private partnership founded in 2014, aims to use the information generated by genome sequencing and genetics studies to systematically improve the identification and prioritisation of drug target...

Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.